We describe a case of a person living with HIV (PWH) with concurrent use of bictegravir and oxcarbazepine. Concomitant use of these pharmacotherapy regimens is considered contraindicated. A review of the literature, therapeutic bictegravir drug concentration monitoring and viral load evaluations allowed the continued current pharmacotherapy prescription of these medications.
GandhiRTLandovitzRJSaxPE, et al.Antiretroviral drugs for treatment and prevention of HIV in adults 2024: recommendations of the international antiviral society—USA panel. JAMA2025; 333(7): 609–628. DOI: 10.1001/jama.2024.24543.
2.
Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services. Available at: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-arv (Accessed January 21, 2025).
MayTWRambeckBJürgensU. Influence of oxcarbazepine and methsuximide on lamotrigine concentrations in epileptic patients with and without valproic acid comedication: results of a retrospective study. Ther Drug Monit1999; 21(2): 175–181. DOI: 10.1097/00007691-199904000-00007.
8.
KandilMMBadowskiMESchrieverCA. Sustained viral suppression with co-administration of oxcarbazepine and dolutegravir. Int J STD AIDS2018; 29(8): 831–833. DOI: 10.1177/0956462417751961.
9.
CattaneoDBaldelliSCozziV, et al.Drug-drug interactions between antiretrovirals and carbamazepine/oxcarbazepine: a real-life investigation. Ther Drug Monit2020; 42(2): 330–334. DOI: 10.1097/FTD.0000000000000715.
10.
PretoriumEKlinkerHRosenkranzB. The role of therapeutic drug monitoring in the management of patients with human immunodeficiency virus infection. Ther Drug Monit2011; 33(3): 265–274. DOI: 10.1097/FTD.0b013e1821b42d1.
11.
MpofuRChandiwanaNSokhelaS, et al.TAF achieves adequate intracellular tenofovir-DP concentrations with rifampicin based TB therapy. In: Conference on Retroviruses and Opportunistic Infections 2025. March 8-12, 2025, San Francisco, CA.
12.
OsualaECNkuhairweINLetsoaloMP, et al.Pharmacokinetics of twice-daily TAF in adults with HIV-associated TB on BID/FTC/TAF and rifampicin. In: Conference on Retroviruses and Opportunistic Infections 2025. March 8-12, 2025, San Francisco, CA.
13.
NaidooANaidooKLetsoaloMP, et al.Effacacy, safety, and PK of BIC/FTC/TAF in adults with HIV and tuberculosis on rifampicin at week 24. In: Conference on Retroviruses and Opportunistic Infections 2024. March 3-6, 2024. Denver, CO, USA.
